118 related articles for article (PubMed ID: 37031678)
1. Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung Adenocarcinoma.
Cavagna RO; Pinto IA; Escremim de Paula F; Berardinelli GN; Sant'Anna D; Santana I; da Silva VD; Da Silva ECA; Miziara JE; Mourão Dias J; Antoniazzi A; Jacinto A; De Marchi P; Molina-Vila MA; Ferro Leal L; Reis RM
Pathobiology; 2023; 90(5):344-355. PubMed ID: 37031678
[TBL] [Abstract][Full Text] [Related]
2. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
3. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
4. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
Molina-Vila MA; Bertran-Alamillo J; Gascó A; Mayo-de-las-Casas C; Sánchez-Ronco M; Pujantell-Pastor L; Bonanno L; Favaretto AG; Cardona AF; Vergnenègre A; Majem M; Massuti B; Morán T; Carcereny E; Viteri S; Rosell R
Clin Cancer Res; 2014 Sep; 20(17):4647-59. PubMed ID: 24696321
[TBL] [Abstract][Full Text] [Related]
5.
Zhao L; Qu X; Wu Z; Li Y; Zhang X; Guo W
Aging (Albany NY); 2020 Jul; 12(14):14556-14568. PubMed ID: 32694238
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
7. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
8. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Saleh MM; Scheffler M; Merkelbach-Bruse S; Scheel AH; Ulmer B; Wolf J; Buettner R
J Thorac Oncol; 2022 Jan; 17(1):76-88. PubMed ID: 34601169
[TBL] [Abstract][Full Text] [Related]
11. Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.
Qian H; Hou C; Zhang Y; Ji S; Zhong C; Li J; Zhang Q; Huang J; Li C; ChengJi
Cancer Genet; 2023 Nov; 278-279():62-70. PubMed ID: 37672936
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
13. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
[TBL] [Abstract][Full Text] [Related]
14. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
[TBL] [Abstract][Full Text] [Related]
15. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
17. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
Barbosa MVR; Cordeiro de Lima VC; Formiga MN; Andrade de Paula CA; Torrezan GT; Carraro DM
Clin Lung Cancer; 2020 Mar; 21(2):e37-e44. PubMed ID: 31889631
[No Abstract] [Full Text] [Related]
20. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]